Technical Service Need help? Our team of experienced experts is here for you with full support.
AKA-340
Halofuginone Hydrochloride
Cat. No.
AKA-340
CAS No.
1217623-74-9
MF
C16H18BrCl2N3O3
MW
451.1
Halofuginone hydrochloride, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Service 
86-28-85159085 
info@aktin.com Technical Data
Description
Documents
Storage and Shipping
References
Product Name
Halofuginone Hydrochloride
CAS No.
1217623-74-9
MF
C16H18BrCl2N3O3
MW
451.1
Specification
98%
Research Area
Halofuginone hydrochloride is a key intermediate of halofuginone, an anticoccidial bulk drug, with good precursor characteristics of anticoccidial activity, providing a core foundation for the synthesis of veterinary bulk drugs.
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Description
Halofuginone hydrochloride, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor. Packing: 10mg, 20mg, 50mg, 100mg, 500mg, 1g, 5g, 10g, 1kg Availability: In stock
Documents
Can't find the right version? Our team of experienced experts is here for you with full support.Contact Us
Storage and Shipping
Store sealed, protected from light, at 2-8°C.
References
[1]. Tsuchida K, et al. Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation. Free Radical Biology & Medicine. 2017 Feb;103:236-247.
[2]. Keller TL, et al. Halofuginone and other Febrifugine derivatives inhibit prolyl-tRNA synthetase. Nature Chemical Biology. 2012 Feb 12;8(3):311-7.
[3]. Cui Z, et al. Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone. Annals of the Rheumatic Diseases. 2016 Sep;75(9):1714-21.
[4]. Tracy L McGaha, et al. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. The Journal of Investigative Dermatology. 2002 Mar;118(3):461-70.
[5]. Pritesh P Jain, et al. Halofuginone, a Promising Drug for Treatment of Pulmonary Hypertension. British Journal of Pharmacology. 2021 Mar 10.
Related Products
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.
